fulvestrant has been researched along with Atypical Ductal Hyperplasia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Korangath, P; Li, S; Merino, VF; Nie, G; Pai, P; Stearns, V; Sukumar, S; Sun, S; Wang, G; Yuan, J | 1 |
| Andrews, P; Carter, B; Gai, L; Kao, KR; Popadiuk, C; Tzenov, YR; Voisey, K; Whelan, K | 1 |
2 other study(ies) available for fulvestrant and Atypical Ductal Hyperplasia
| Article | Year |
|---|---|
Intraductal fulvestrant for therapy of ERα-positive ductal carcinoma in situ of the breast: a preclinical study.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Injections, Intralesional; Mammary Glands, Animal; MCF-7 Cells; Mice; Rats; Xenograft Model Antitumor Assays | 2019 |
Selective estrogen receptor modulators and betulinic acid act synergistically to target ERα and SP1 transcription factor dependent Pygopus expression in breast cancer.
Topics: Antineoplastic Agents; Betulinic Acid; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Hydroxytestosterones; Intracellular Signaling Peptides and Proteins; Microarray Analysis; Pentacyclic Triterpenes; Promoter Regions, Genetic; Selective Estrogen Receptor Modulators; Signal Transduction; Sp1 Transcription Factor; Tamoxifen; Triterpenes | 2016 |